News and updates
First Horizon 2020 Work Programme update – budget, and launch of FTI and innovat…

On July 22, the European Commission announced an update of the Work Programme 2014-2015. Hematologists should be aware that in 2015 opportunities are available to them in the Societal Challenge Health, demographic change and wellbeing.
The importance of education and collaboration for the treatment of patients

Today, EU Reporter published an article by Ulrich Jäger, past president of the European Hematology Association (EHA) and chair of the European Affairs Committee, highlighting the importance of education and collaboration for the treatment of patients.
Ibrutinib improves survival in CLL and SLL patients: Results From the RESONATE …

Milan, June 13, 2014 - On Behalf of the RESONATE Investigators, Dr Hillmen will present the results from the Phase III trial in CLL and SLL patients.
ABT-199: Novel Bcl-2 specific inhibitor updated results confirm substantial acti…

Milan, June 13, 2014 – Promising results from phase-I study for CLL patients will be presented by Dr John Seymour.
Do generics of imatinib jeopardize patient safety for the sake of saving money? …

Milan, June 13, 2014 – Dr Zafer Başlar will present the results of a multicenter study that was conducted in Turkey to evaluate the efficacy and tolerability of generics for CML patients.
Treatment of acute lymphoblastic leukemia by activation of patient's immune cell…

Milan, June 13, 2014 – Dr Nicola Gökbuget will explain also on behalf of Max Topp, the results of two abstracts that will be presented during the 19th Congress of EHA about the treatment of ALL.
Gdf -11 a new target to improve anemia in thalassemia.

Milan, June 13, 2014 – New possible treatment options for thalassemia patients will be presented by Dr Olivier Hermine at the 19th Congress of EHA.
Can Eltrombopag help children with ITP say goodbye to bleeding?

Milan, June 13, 2014 – Results from a large international study on pediatric ITP will be presented at the 19th Congress of EHA by Dr John Grainger.
Pivotal Ruxolitinib Data Shows Promise for Patients with PV.

Milan, June 13, 2014 – Dr Alessandro Vannucchi will present the promising results of a Phase III trial for polycythemia vera patients.
Mutiple Myeloma at the 19th Congress of the European Hematology Association: Wha…

Multiple myeloma (MM), a proliferation (growth) of malignant plasma cells in the bone marrow destroying bones, accounts for 10% of all hematologic malignancies. Approximately 45.000 new cases are diagnosed each year together in the US and Europe. MM is mainly a disease of elderly people with age at diagnosis between 65-70 years.
Harnessing new developments in genomics to improve outcome for children with poo…

The dramatic improvement in outcome for children with acute lymphoblastic leukemia is one of the major achievements in hematology in the last 40 years. However, while 90% of children with this disease can now be cured, the outlook has not been so good for the less common type of childhood leukemia, acute myeloid leukemia (AML). Although only 1 in 7 children with leukemia have AML, half of these children will die from their disease. The challenge now is to harness the new developments in genomics to improve the outcome for these children.
Advances from genome sequencing are paving the way to personalized treatment for…

Blood cancers (leukemias) are life-threatening diseases that can devastate the lives of patients and their families. Great progress has been made in treatments to improve the survival of these otherwise invariably fatal conditions. Major advances in the understanding of leukemia genetics for genome sequencing of individual patients has taken us one step further towards realizing personalized medicine for many patients.
Leading Medical Organizations Join Forces Globally to Launch First-Ever World Th…

The International Society on Thrombosis and Haemostasis (ISTH) partners with thrombosis related organizations from every continent to launch World Thrombosis Day focused on single cause of top 3 cardiovascular deaths worldwide.
EHA endorses and supports the initiative for this World Thromobis Day.
Treatment, medicine and hematology research: What patients want and doctors need…

The European Hematology Association is organizing its 19th Congress in Milan, Italy- June 12-15, 2014.
Following last year’s successful introduction, the EHA congress program will be complemented by a dedicated advocacy track. This track combines all patient and policy related sessions into one comprehensive full-day program on Saturday.
European Hematologists will discuss breakthroughs in blood disorders in Milan, I…

The Board of the European Hematology Association (EHA) has the pleasure to cordially invite you, as a member of the press, to the 19th Congress of EHA.More than 9,500 participants from around the world are expected at the upcoming 19th Congress of the European Hematology Association at the MiCo - Milano Congressi in Milan, Italy from June 12-15, 2014.